168 related articles for article (PubMed ID: 26446567)
1. Discovery of a dual-targeting organometallic ruthenium complex with high activity inducing early stage apoptosis of cancer cells.
Du J; Zhang E; Zhao Y; Zheng W; Zhang Y; Lin Y; Wang Z; Luo Q; Wu K; Wang F
Metallomics; 2015 Dec; 7(12):1573-83. PubMed ID: 26446567
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines.
Du J; Kang Y; Zhao Y; Zheng W; Zhang Y; Lin Y; Wang Z; Wang Y; Luo Q; Wu K; Wang F
Inorg Chem; 2016 May; 55(9):4595-605. PubMed ID: 27093574
[TBL] [Abstract][Full Text] [Related]
4. Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.
Zheng W; Luo Q; Lin Y; Zhao Y; Wang X; Du Z; Hao X; Yu Y; Lü S; Ji L; Li X; Yang L; Wang F
Chem Commun (Camb); 2013 Nov; 49(87):10224-6. PubMed ID: 23856988
[TBL] [Abstract][Full Text] [Related]
5. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
[TBL] [Abstract][Full Text] [Related]
6. Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers.
Li L; Wong YS; Chen T; Fan C; Zheng W
Dalton Trans; 2012 Jan; 41(4):1138-41. PubMed ID: 22159211
[TBL] [Abstract][Full Text] [Related]
7. Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.
Zhao J; Li S; Wang X; Xu G; Gou S
Inorg Chem; 2019 Feb; 58(3):2208-2217. PubMed ID: 30675781
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
9. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
[TBL] [Abstract][Full Text] [Related]
10. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
[TBL] [Abstract][Full Text] [Related]
11. Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.
Jayanthi E; Kalaiselvi S; Padma VV; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2016 Jan; 45(4):1693-707. PubMed ID: 26699435
[TBL] [Abstract][Full Text] [Related]
12. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
13. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
14. Dual Antimicrobial-Anticancer Potential, Hydrolysis, and DNA/BSA Binding Affinity of a Novel Water-Soluble Ruthenium-Arene Ethylenediamine Schiff base (RAES) Organometallic.
Zahirović A; Fetahović S; Feizi-Dehnayebi M; Višnjevac A; Bešta-Gajević R; Kozarić A; Martić L; Topčagić A; Roca S
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Oct; 318():124528. PubMed ID: 38801789
[TBL] [Abstract][Full Text] [Related]
15. Half-Sandwich Iridium and Ruthenium Complexes: Effective Tracking in Cells and Anticancer Studies.
Li J; Guo L; Tian Z; Zhang S; Xu Z; Han Y; Li R; Li Y; Liu Z
Inorg Chem; 2018 Nov; 57(21):13552-13563. PubMed ID: 30289251
[TBL] [Abstract][Full Text] [Related]
16. Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.
Bhattacharyya S; Purkait K; Mukherjee A
Dalton Trans; 2017 Jul; 46(26):8539-8554. PubMed ID: 28638907
[TBL] [Abstract][Full Text] [Related]
17. Chiral ruthenium complexes induce apoptosis of tumor cell and interact with bovine serum albumin.
Yuan F; Chen X; Liu Y; Zhang T; Sun D; Liu J
Chirality; 2012 Feb; 24(2):174-80. PubMed ID: 22180296
[TBL] [Abstract][Full Text] [Related]
18. Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.
Huang H; Zhang P; Chen Y; Ji L; Chao H
Dalton Trans; 2015 Sep; 44(35):15602-10. PubMed ID: 26245234
[TBL] [Abstract][Full Text] [Related]
19. Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development.
Babak MV; Meier SM; Legin AA; Adib Razavi MS; Roller A; Jakupec MA; Keppler BK; Hartinger CG
Chemistry; 2013 Mar; 19(13):4308-18. PubMed ID: 23341078
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of ruthenium(II) arene complexes bearing 1,2,3,4-tetrahydroisoquinoline amino alcohol ligands.
Chelopo MP; Pawar SA; Sokhela MK; Govender T; Kruger HG; Maguire GE
Eur J Med Chem; 2013 Aug; 66():407-14. PubMed ID: 23827181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
